Chimeric antigen receptor-modified T cells in CLL [5]

New England Journal of Medicine

Volumn 365, Issue 20, 2011, Pages 1937-1939

  Yeh, Chi Chun ^a   Kochenderfer, James N ^b   Rosenberg, Steven A ^b   Kalos, Michael ^c   Porter, David L ^c   June, Carl H ^c   Urba, Walter J ^d   Longo, Dan L ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Providence Cancer Center

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CHIMERIC ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VIRUS VECTOR; CD19 ANTIGEN; ANTINEOPLASTIC AGENT; DNA;

CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLONAL VARIATION; HUMAN; IN VIVO STUDY; LETTER; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHATIC LEUKEMIA; MALE; NOTE; ADOPTIVE TRANSFER; DNA MODIFICATION; FOLLICULAR LYMPHOMA; IMMUNOGLOBULIN DEFICIENCY; REMISSION;

ANTIGENS, CD19; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOID; MALE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 81455141816     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1111004     Document Type: Letter

References (2)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
2. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004;350:913-22. (Pubitemid 38252539)